|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 9/15/14 Foamix Pharmaceuticals Ltd. 8-A12B 1:15K Summit Fin’l Pri… LLC/FA |
Document/Exhibit Description Pages Size 1: 8-A12B Registration of a Class of Securities HTML 12K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-A
For Registration of Certain Classes of
Securities
Pursuant to Section 12(b) or 12(g) of the
Securities Exchange Act
Foamix Pharmaceuticals Ltd.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
|
Israel (State or other jurisdiction of incorporation) |
Not Applicable (IRS Employer Identification No.) |
|
2 Holzman Street, Weizmann Science Park Rehovot, 76704, Israel (Address of principal executive offices) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
Title
of Each Class |
Name
of Each Exchange on which | |
| Ordinary Shares, par value NIS 0.16 per share | The NASDAQ Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box. o
Securities Act registration statement file number to which this form relates: 333-198123
Securities to be registered pursuant to Section 12(g) of the Act: None
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1: Description of Registrant's Securities to be Registered
The description under the heading “Description of Share Capital” relating to the Registrant's Ordinary Shares par value NIS 0.16 per share (the “Ordinary Shares”), included in the Registrant's Registration Statement on Form F-1 (Registration No. 333-198123), as amended from time to time (the “Registration Statement”) filed with the Securities and Exchange Commission, is incorporated herein by reference. The final prospectus will be filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, and, upon filing, shall be deemed to be incorporated herein by reference.
Item 2: Exhibits
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are quoted on the NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
| Foamix Pharmaceuticals Ltd. | ||
| (Registrant) | ||
| Dated: September 15, 2014 | By: | /s/ Dov Tamarkin |
| Name: | Dov Tamarkin | |
| Title: | Chief Executive Officer | |
| This ‘8-A12B’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/15/14 | None on these Dates | ||
| List all Filings | ||||